Copyright
©The Author(s) 2021.
World J Clin Cases. Jul 26, 2021; 9(21): 6041-6048
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6041
Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6041
Time of therapy | Treatment | Best efficacy | PFS (mo) |
November 2014 | ABVD × 6 cycles | CR | 16 |
March 2016 | AVD × 1 cycle | Unknown | - |
September 2016 | AVD × 1 cycle | Unknown | - |
October 2016 | GVD × 4 cycles | PD | 4.8 |
October 2017 | GVD × 6 cycles | SD | 8.8 |
July 2018 | ESHAP × 1 cycle | PD | 0.9 |
October 2018 | AK105 × 9 cycles | PR | 3.5 |
July 2019 | IBI188 × 16 wk | SD | 3.6 |
November 2019 | DICE × 2 cycles | PD | 1.3 |
February 2020 | F0002-ADC × 1 cycle | PD | 0.6 |
March 2020 | Decitabine plus tislelizumab | PR | 11.5 |
- Citation: Ding XS, Mi L, Song YQ, Liu WP, Yu H, Lin NJ, Zhu J. Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report. World J Clin Cases 2021; 9(21): 6041-6048
- URL: https://www.wjgnet.com/2307-8960/full/v9/i21/6041.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i21.6041